Evidence map›Paper›PMID 24646488›Full record

ArticleClinical pharmacology and therapeutics2014

A horizon-prioritizing method can identify gaps among genomic application guidelines.

L Li

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

L LiDepartment of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis, Indiana, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In light of the increasing need by decision makers for a method of evaluating genomic applications based on the weight of evidence for their efficacy, several agencies have developed systems of classification. Here I review the horizon-scanning method for prioritizing genomics applications as described by Dotson et al. in this issue of CPT. Using the examples of the authors' Tier 1/Green classification for KRAS and Tier 2/Yellow for TPMT, I discuss differences between the guidelines issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and those by the National Comprehensive Cancer Network (NCCN). Additionally, I offer suggestions regarding classification of the Tier 3/Red genomics applications and the reproducibility of the data-curating algorithm of the horizon-scanning method.

Indexed as

Decision MakingGenomicsHumansPharmacogenetics

Identifiers

PMID24646488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.